Fierce Healthcare's 2021 Women of Influence Awards
To view this email as a web page, click here

Today's Rundown

Featured Story

Zaks, fresh from making millions at Moderna, takes venture partner post at OrbiMed

Tal Zaks has revealed his next job. Weeks after leaving Moderna, Zaks has taken up a venture partner post at OrbiMed—where he is joined by another storied biopharma executive.

read more

Top Stories

Inovio falls victim to AstraZeneca's 'usual pipeline pruning' as human papillomavirus cancer vaccine deal axed

AstraZeneca is wielding the ax to a bloated pipeline and Inovio has found itself the latest victim. MedImmune, an AstraZeneca unit, has terminated a collaboration agreement with Inovio for the cancer immunotherapy MEDI0457, which was being developed to target cancers caused by certain types of the human papillomavirus.

read more

Cytokines claimed spotlight due to COVID-19. Now, Merck will work with Synthekine to understand their role in autoimmune disorders

The world got a little more steeped in cytokine knowledge because of the small protein's role in COVID-19, and, now, Merck will study how they work in autoimmune diseases through a $525 million biobucks deal with Synthekine. 

read more

Sponsored: A New Reference Model for Clinical Trial Recruitment, Enrollment and Retention Success

Rare diseases demand a modern recruitment approach grounded in uncovering the ideal, medically-eligible patient population with the highest propensity for study enrollment and retention.

read more

LianBio snags $325M IPO, slightly bigger than the multi-partnered biotech's 2020 series A

Partner-heavy biotech LianBio secured $325 million in its Wall Street debut to fund a series of trials across cardiovascular, oncology, ophthalmology, inflammatory and respiratory diseases. The Shanghai biotech raised $310 million in a series A last year and has lined up partners like Bristol Myers Squibb's MyoKardia, BridgeBio, Tarsus, Lyra and others.

read more

Sponsored: Intranasals in Clinic Now Positioned for $71 Billion Nasal Delivery Market

Australia’s Avance Clinical: how intranasal biotechs can expedite trials with rapid approval processes - including no IND and a 43.5% incentive rebate - to tap $71 billion market

read more

Gilead bought his last biotech. Now, Helin is back with another cancer startup

The founder of a biotech bought by Gilead has birthed another startup. Dania Therapeutics begins life with a discovery program based on Kristian Helin’s work and plans to advance small-molecule inhibitors of new oncology targets.

read more

Lengo's hiring spree shows no signs of slowing as it hires Pfizer veteran Murray as VP of research

Lengo Therapeutics has named a slate of new hires in recent months and is back at it again, nabbing Turning Point’s Brion Murray, Ph.D., as its senior vice president of research.

read more

Fierce Healthcare's 2021 Women of Influence Awards

We are honoring leaders who have made a measurable impact on healthcare in the past year and who have paved the way forward for women and men alike. These leaders epitomize innovation, passion and ingenuity.

read more

MIT team uncovers differences in T cells that drive immuno-oncology resistance in lung cancer

MIT scientists discovered a subset of T cells that become dysfunctional because of changes in gene expression that occur while they’re being activated in the lymph nodes. They reactivated the T cells in mouse models of non-small cell lung cancer with two cytokines, offering insights into improving responses to immuno-oncology drugs in people, they said.

read more

Novartis keeps the leukemia innovation coming with FDA approval for Gleevec follow-on Scemblix as Tasigna patent cliff nears

About two decades ago, Novartis transformed leukemia treatment with the introduction of Gleevec. Now, the Swiss pharma has ushered a third-generation therapy targeted against the blood cancer across the regulatory finish line.

read more

BD inks BARDA contract to develop COVID tests for the long future of the pandemic

BD has inked a public-private partnership with the U.S. government to ready its current lines of COVID-19 diagnostics for the long haul of the pandemic—by developing combination tests that simultaneously screen for the flu and other infectious diseases from a single sample.

read more

Resources

2021 Report: Clinical Trial Management in a Post-Pandemic World

New market research provides valuable insight into the impact of adaptations made in clinical trials during the pandemic.

Whitepaper: A Checklist for eCOA Solution Deployment

Every detail is important when selecting a new eCOA solution; learn more about the current eCOA landscape, best practices, and crucial considerations for successful eCOA solution deployment in this white paper.

Whitepaper: Enhance the cost-effectiveness of your cGMP chemical supply chain

Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific

Paid Marketplace: Online Graduate Programs Designed for Your Career

Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more.

Report: New research indicates an accelerated shift to decentralized clinical trials

New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19.

eBook: Get solutions to market faster

Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization.

Events